Skip to main content
Clinical Trials/NCT02419482
NCT02419482CompletedNot Applicable

Improving Reproductive Function in Women With Polycystic Ovary Syndrome by High Intensity Interval Training: A Randomized Controlled Trial.

Norwegian University of Science and Technology2 sites in 2 countries64 target enrollmentStarted: June 1, 2015Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
64
Locations
2
Primary Endpoint
Menstrual frequency

Study Overview

Brief Summary

The aim is to investigate whether 16 weeks of high intensity interval training, followed by 36 weeks of home-based exercise, will improve menstrual frequency in women with Polycystic Ovary Syndrome (PCOS) compared with a non-exercising control group.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 45 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Polycystic ovary syndrome (PCOS) according to the Rotterdam criteria

Exclusion Criteria

  • •Regular high intensity endurance (two or more times per week of vigorous exercise).
  • •Concurrent treatments (insulin sensitizers or drugs known to affect gonadotropin or ovulation, with a wash out period of 1 months prior to inclusion).
  • •On-going pregnancy.
  • •Breast feeding within 24 weeks
  • •Cardiovascular disease or endocrine disorders

Arms & Interventions

4x4 minutes interval training

Experimental

4x4 minutes high intensity interval training with 4 minute intervals

Intervention: 4x4 minutes high intensity interval training (Behavioral)

10x1 minute interval training

Experimental

10x1 minute high intensity interval training with 1 minute intervals

Intervention: 10x1 minute high intensity interval training (Behavioral)

control

No Intervention

Physical activity recommended

Outcomes

Primary Outcomes

Menstrual frequency

Time Frame: 1 year

Electronic menstrual diary

Secondary Outcomes

  • Aerobic capacity(16 weeks, and 36 weeks)
  • Physical activity(16 weeks, and 36 weeks)
  • Hormone profile, blood lipids and blood values(16 weeks, and 36 weeks)
  • Body composition(16 weeks, and 36 weeks)
  • Endothelial function(16 weeks, and 36 weeks)
  • Insulin sensitivity(16 weeks, and 36 weeks)
  • Intima-media thickness(16 weeks, and 36 weeks)
  • Oxidative capacity(16 weeks, and 36 weeks)
  • Low-grade systematic inflammation(16 weeks, and 36 weeks)
  • Adipose tissue morphology and function(16 weeks, (and 36 weeks if funded))
  • Pregnancy rate(16 weeks , and 36 weeks)
  • Blood pressure(16 weeks, and 36 weeks)
  • Quality of life(36 weeks)
  • Adipose tissue mRNA expression(16 weeks, (and 36 weeks if funded))
  • Enjoyment(weekly up to 16 weeks)
  • ovarian morphology(16 weeks, and 36 weeks)
  • Diet(36 weeks)
  • Quality of life(16 weeks)
  • Diet(16 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials